<DOC>
	<DOCNO>NCT00352807</DOCNO>
	<brief_summary>The purpose study obtain assay human aqueous sample follow pre-operative dose 0.1 % Brimonidine Purite™ ( pH 7.8 ) 0.15 % Brimonidine Purite® ( pH 7.2 ) patient undergo routine cataract surgery order evaluate aqueous concentration two formulations.Study hypothesis : The aqueous humor concentration 45 minute follow dose 0.1 % Brimonidine Purite™ ( pH 7.8 ) comparable 0.15 % Brimonidine Purite® ( pH 7.2 )</brief_summary>
	<brief_title>Absorption Brimonidine Ophthalmic Solution Aqueous Humor Cataract Patients</brief_title>
	<detailed_description>The purpose study obtain assay human aqueous sample follow pre-operative dose 0.1 % Brimonidine Purite™ ( pH 7.8 ) 0.15 % Brimonidine Purite® ( pH 7.2 ) patient undergo routine cataract surgery order evaluate aqueous concentration two formulation .</detailed_description>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>All subject must : 1 . Be willing able provide write Informed Consent 2 . Be able willing follow instruction likely complete entire course study . 3 . Be male female race least 18 year age . 4 . Have visually significant cataract elect undergo cataract surgery . No subject may : 1 . Known allergy sensitivity study medication component 2 . Contraindications brimonidine therapy : concurrent use monoamine oxidase ( MAO ) inhibitor therapy 3 . Have active ocular disease glaucoma ocular hypertension would interfere study parameter ( : uveitis , ocular infection , severe dry eye ) . Patients mild chronic blepharitis , agerelated macular degeneration , background diabetic retinopathy may enrol discretion investigator . 4 . Any ocular surgery ( include laser , refractive , intraocular filtering surgery , ocular surgery ) within 3 month . 5 . Require use ocular medication ( include glaucoma medication ) , except intermittent use artificial tear . 6 . Have corneal abnormality would interfere ability obtain adequate sample safely shallow anterior chamber would make obtain aqueous sample difficult time surgery opinion investigator . 7 . Be concurrently enrol investigational drug device study participation within last 30 day investigational drug device study . 8 . Be pregnant , nursing , plan pregnancy , childbearing potential use reliable form contraception . 9 . Have situation condition investigator 's opinion may put subject significant risk , may confound study result , may interfere significantly participation study , significant cardiovascular disease , hepatic renal impairment , depression , Raynaud 's , orthostatic hypotension ; uncontrolled high blood pressure . concomitant use potential CNS depressant tricyclic , ( Amendment 1 , May 25 , 2005 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Cataract</keyword>
</DOC>